X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Apotex Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of rosacea, in Canada.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SEARCHLIGHT PHARMA INC
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 06, 2023
Details:
IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.
Lead Product(s): Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples. The drug will be manufactured at the group's topical facility at Ahmedabad, Zydus Lifesciences.
Lead Product(s): Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Adapalene/Benzoyl Peroxide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
EPSOLAY (Benzoyl Peroxide) is a topical cream containing benzoyl peroxide (BPO), 5%, for the treatment of bumps and blemishes (inflammatory lesions) of rosacea in adults.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
Approval of EPSOLAY (benzoyl peroxide) is supported by data from Phase 3 trial, which demonstrated reduction in inflammatory lesions of rosacea by nearly 70% by end of both 12-week trials vs. 38-46% with vehicle.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galderma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
TWYNEO is a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2022
Details:
IDP-126 Gel, an investigational drug, efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: randomized phase 2 and phase 3 studies of the first triple-combination drug.
Lead Product(s): Clindamycin Phosphate,Benzoyl Peroxide,Adapalene
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma ; Proactiv YK ; The Proactiv Company ; used in the business of developing, manufacturing, marketing, selling and distributing products sold under the Proactiv, Skin brands.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Proactiv
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries
Deal Size: $99.3 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand. Alchemee's flagship brand, Proactiv, is America’s 1 acne routine and has been used and trusted by millions around the world for more than 25 years.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Proactiv
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 28, 2022
Details:
Adapalene and Benzoyl Peroxide combination is used to treat acne. It works by killing the bacteria that cause acne and by keeping the skin pores clean.
Lead Product(s): Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
TWYNEO combines, for the first time, two of the most commonly used topical agents available for the treatment of acne into a single application. TWYNEO is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
The NDA filing is based on two positive, identical Phase 3 randomized, double-blind, multicenter, 12-week, clinical trials that evaluated the safety and efficacy of Epsolay compared to vehicle in patients with papulopustular rosacea.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Consistent with Sol-Gel’s prior agreements, Perrigo will seek regulatory approval with the U.S. FDA for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the United States.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sol-Gel Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
Details:
The fund will be directed towards the NDA filling of company's drug candidates- Epsolay and Twyneo.
Lead Product(s): Benzoyl Peroxide,Tretinoin
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: M. Arkin Dermatology Ltd
Deal Size: $28.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 13, 2020
Details:
The Company intends to use the net proceeds from the Offering to fund pre-commercialization and launch activities for Epsolay® and Twyneo®, research and development activities and the remainder for working capital and other general corporate purposes.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Epsolay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies LLC
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 14, 2020
Details:
Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea. Results pave the way for NDA submission in 2020.
Lead Product(s): Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
